BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19796673)

  • 21. Biomarkers for Alzheimer's disease.
    Sonnen JA; Keene CD; Montine KS; Li G; Peskind ER; Zhang J; Montine TJ
    Expert Rev Neurother; 2007 Aug; 7(8):1021-8. PubMed ID: 17678497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers of neurodegenerative disorders: how good are they?
    Rachakonda V; Pan TH; LE WD
    Cell Res; 2004 Oct; 14(5):347-58. PubMed ID: 15538967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Is late-onset schizophrenia related to neurodegenerative processes? A review of literature].
    Lagodka A; Robert P
    Encephale; 2009 Sep; 35(4):386-93. PubMed ID: 19748376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.
    Otto M; Lewczuk P; Wiltfang J
    Methods; 2008 Apr; 44(4):289-98. PubMed ID: 18374272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future.
    Ghidoni R; Benussi L; Paterlini A; Albertini V; Binetti G; Emanuele E
    Neurodegener Dis; 2011; 8(6):413-20. PubMed ID: 21709402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.
    Portelius E; Zetterberg H; Gobom J; Andreasson U; Blennow K
    Expert Rev Proteomics; 2008 Apr; 5(2):225-37. PubMed ID: 18466053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
    Lewczuk P; Kamrowski-Kruck H; Peters O; Heuser I; Jessen F; Popp J; Bürger K; Hampel H; Frölich L; Wolf S; Prinz B; Jahn H; Luckhaus Ch; Perneczky R; Hüll M; Schröder J; Kessler H; Pantel J; Gertz HJ; Klafki HW; Kölsch H; Reulbach U; Esselmann H; Maler JM; Bibl M; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2010 Feb; 15(2):138-45. PubMed ID: 18663368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of CSF biomarkers in the diagnostics of memory diseases].
    Remes A; Leikola M; Majamaa K; Nikkanen M; Ruokonen LI; Rusanen M; Tapiola T; Ylikotila P; Vallittu AM; Pirttilä T
    Duodecim; 2009; 125(20):2215-22. PubMed ID: 19998760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going?
    Lewczuk P; Kornhuber J
    Expert Rev Proteomics; 2011 Aug; 8(4):447-58. PubMed ID: 21819301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease.
    Kantarci K
    Expert Rev Neurother; 2005 Sep; 5(5):663-70. PubMed ID: 16162090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of biomarkers in the elderly: current and future challenges.
    Sunderland T; Gur RE; Arnold SE
    Biol Psychiatry; 2005 Aug; 58(4):272-6. PubMed ID: 16018985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional Genomics meets neurodegenerative disorders. Part II: application and data integration.
    Hoerndli F; David DC; Götz J
    Prog Neurobiol; 2005 Jun; 76(3):169-88. PubMed ID: 16169146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteome studies of CSF in AD patients.
    Davidsson P; Sjögren M
    Mech Ageing Dev; 2006 Feb; 127(2):133-7. PubMed ID: 16293296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomics in neurosciences.
    Drabik A; Bierczynska-Krzysik A; Bodzon-Kulakowska A; Suder P; Kotlinska J; Silberring J
    Mass Spectrom Rev; 2007; 26(3):432-50. PubMed ID: 17405153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biomarkers for early diagnosis of Alzheimer's disease: current update and future directions].
    Malaplate-Armand C; Desbene C; Pillot T; Olivier JL
    Rev Neurol (Paris); 2009; 165(6-7):511-20. PubMed ID: 19041993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases.
    Verbeek MM; De Jong D; Kremer HP
    Ann Clin Biochem; 2003 Jan; 40(Pt 1):25-40. PubMed ID: 12542908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF biomarkers for mild cognitive impairment.
    Blennow K
    J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.